IXJ ETF: What Is It? — A Complete Guide to Returns, Expense Ratio, Holdings, and Alternative ETFs
A global healthcare sector ETF. A defensive, diversified product centered on large-cap US pharmaceutical and biotech names, with exposure to developed-market healthcare companies.
SubscribeWhat is this ETF?
A passive ETF that tracks the S&P Global 1200 Healthcare Index, holding US and developed-market healthcare companies on a market-cap-weighted basis. It spans a broad range of sub-sectors, including pharmaceuticals, biotechnology, medical devices, and healthcare services.
It is well suited for medium- to long-term investors seeking diversified exposure to the global healthcare sector.
The fund is a passive (index-tracking) ETF launched in 2001 by BlackRock (iShares).
How does it invest?
| Item | Details |
|---|---|
| Tracking Index | S&P Global 1200 Healthcare (Capped) |
| Management Style | Passive (Index Tracking) |
| Rebalancing Frequency | Once per Quarter |
| Dividend Schedule | Semi-Annual |
| Total Expense Ratio | 0.38% |
It holds global healthcare sector companies on a market-cap-weighted basis, with a heavy US weighting while also including healthcare companies from developed markets such as Europe and Asia. A cap rule is applied to prevent excessive concentration in any single security.
- Global diversification that extends beyond the US to include developed-market healthcare companies
- Broad coverage across healthcare sub-sectors, including pharmaceuticals, biotechnology, medical devices, and healthcare services
Size and Cost
Assets under management (AUM) stand at $4.6B, with a total expense ratio of 0.38% annually.
Compared with single-country US healthcare sector ETFs, this fund carries additional non-US exposure, so investors should also factor in currency effects.
Performance and Flows
1-Year Price Performance
Dividend & Yield
52-Week Price RangeThanks to the defensive characteristics of the healthcare sector, it tends to show relatively resilient performance during market downturns, although short-term volatility can arise from interest-rate movements and key pharmaceutical clinical results.
During periods of rising economic uncertainty, demand for defensive sectors tends to increase, drawing inflows into healthcare ETFs, while during phases of expected economic recovery, preference for growth-oriented stocks can lead to relative outflows.
Strengths and Weaknesses
Global diversification and defensive characteristics are the key strengths, but the expense level and currency exposure should be reviewed in advance.
� Key Strengths
⚠️ Points to Watch
Alternative ETFs and Related Products
The ETFs shown in the table, including IXN (Technology), IXC (Energy), and EXI (Industrials), are other sector ETFs from the same S&P Global 1200 family and can be used for sector allocation comparisons. As direct substitutes within healthcare, XLV, which holds only the US healthcare sector, can be considered, as well as RSPH for dividend-focused healthcare exposure and RXI for global dividend-oriented healthcare exposure.
Peer Comparison ETFs| Ticker | Name | Price | Change | AUM | Total Expense Ratio | Dividend Yield | 1Y |
|---|---|---|---|---|---|---|---|
 IXN | iShares Global Tech ETF | $132.55 | -0.4% | $8.8B | 0.37% | 0.26% | +23.4% |
 IXC | iShares Global Energy ETF | $58.76 | -4.1% | $3.3B | 0.37% | 2.68% | +42.3% |
 EUFN | iShares MSCI Europe Financials ETF | $39.80 | +5.1% | $2.9B | 0.48% | 4.15% | +18.6% |
 PICK | iShares MSCI Global Metals & Mining Producers ETF | $55.76 | +2.3% | $2.2B | 0.39% | 2.36% | +25.0% |
 EXI | iShares Global Industrials ETF | $189.74 | -0.2% | $1.4B | 0.38% | 1.12% | +10.5% |
Top Holdings| Ticker | Name | Weight | Price | Change | Market Cap | P/E | Dividend Yield |
|---|---|---|---|---|---|---|---|
| LLY | Lilly(Eli) & Co | 0.20% | $1417.99 | +0.6% | $1.33T | 46.6 | 0.48% |
| JNJ | Johnson & Johnson | 0.15% | $276.32 | +3.8% | $665.2B | 41.9 | 1.93% |
| ABBV | Abbvie Inc | 0.10% | $294.83 | +3.1% | $521.0B | 50.7 | 2.32% |
| UNH | Unitedhealth Group Inc | 0.04% | $409.38 | +1.2% | $367.5B | 23.4 | 2.2% |
| MRK | Merck & Co Inc | 0.08% | $150.36 | +3.9% | $371.0B | 153.6 | 2.26% |
| AZN | Astrazeneca plc | 0.04% | $189.01 | +2.8% | $293.1B | 26.8 | 1.77% |
Investor Checklist
Key points to review before investing in IXJ. While the fund offers global healthcare diversification, it is important to fully examine the expense level, currency exposure, and regulatory risks in advance.
| Checkpoint | What to Verify | Current Status |
|---|---|---|
| 💵 Expense Ratio | Assess the cumulative cost impact over long-term holding periods | Mid-range within the category |
| � Non-US Weight | Check the currency exposure of holdings outside the US | Includes developed-market healthcare |
| 📊 Top-Holding Concentration | Monitor the weight trend of large-cap pharma and biotech names | Concentrated in top market-cap names |
| ⚖️ Regulatory Environment | Track changes in drug-pricing rules and patent policies | Requires monitoring |
Changes in healthcare regulations and patent expirations of major pharmaceutical companies can affect the overall portfolio, and currency fluctuations stemming from non-US holdings also impact returns.
This fund is a suitable choice for investors seeking diversified exposure to the global healthcare sector through a single product. For investors whose goal is US-only healthcare exposure, XLV may serve as a lower-cost alternative.
SubscribeDisclaimer: This content is for informational purposes only and does not constitute investment advice. All investment responsibility lies with the investor.
This article reflects information as of September 3, 2026.
Today's 5 AI picks, all free